216-114-0

Applied Filters:

Keyword:'216-114-0'

Showing 1-1 of 1 result for "216-114-0" within Papers

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Frank Weidemann et al.

Journal of the American Society of Nephrology : JASN, 25(4), 837-849 (2014-02-22)

Because of the shortage of agalsidase-beta in 2009, many patients with Fabry disease were treated with lower doses or were switched to agalsidase-alfa. This observational study assessed end-organ damage and clinical symptoms during dose reduction or switch to agalsidase-alfa. A

Page 1 of 1